查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1961056

全球口服蛋白和胜肽市场：市场规模、产业动态、机会分析及预测（2026-2035 年），依产品类型、成分、应用和最终用户划分

Global Oral Protein and Peptides Market: By Product Type, By Source, By Application, By End-User - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 280 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球口服蛋白和胜肽市场持续快速成长，预计到 2025 年将达到 95 亿美元，并预计在 2035 年实现指数级增长，达到 473.3 亿美元。这一令人瞩目的成长意味着在 2026 年至 2035 年的预测期内，复合年增长率 (CAGR) 约为 17.42%。这一强劲的成长势头表明，口服蛋白和胜肽疗法在各个医疗保健领域的重要性日益凸显，应用也日益广泛。

2025 年的关键发展包括产业领导者雀巢健康科学和达能的策略性产品组合调整。两家公司都认识到口服蛋白和胜肽作为功能性成分在特定健康益处方面的潜力，并采取重要举措，以打破食品和製药行业之间的传统界限。 两家公司的投资都集中在酵素水解技术上，该技术可以将长链蛋白质分解成具有生物活性的小胜肽。

市场趋势展望

口服蛋白质和胜肽市场的特点是，成熟的製药公司积极参与其中，优先研发以开发传统注射疗法的口服替代方案。这些公司意识到对微创治疗的需求日益增长，因此正积极投资于创新技术，以提高口服製剂的疗效和生物利用度。

2025 年的显着趋势包括雀巢健康科学和达能等领先公司进行策略性产品组合调整。两家公司都采取了果断措施，整合并模糊食品和製药行业之间的界限，利用其在营养和健康科学方面的专业知识，开发具有特定治疗功效的产品。这些努力的核心是对酶水解技术的大量投资，该技术可以将长链蛋白质分解成具有生物活性的小肽。

为了应对供应方面的挑战，製药巨头礼来和诺和诺德已投入大量资金扩大其生产能力。两家公司宣布计划在2024年至2025年间投资超过180亿美元，用于扩建和升级其位于关键地点（包括北卡罗来纳州和丹麦）的胜肽合成设施。这些扩建计画旨在稳定供应链，满足不断增长的全球需求，并加速先进胜肽疗法的研发和生产。

核心成长驱动因子

糖尿病、癌症和胃肠道疾病等慢性病的日益增多是口服蛋白质和胜肽类疗法需求的主要驱动因素。这些疾病通常需要长期甚至终身用药，而传统上是透过痛苦且不便的每日註射给药。频繁注射的负担不仅影响患者的依从性，还会影响生活质量，因此开发有效的口服替代疗法是医疗保健领域的关键优先事项。

新机遇

影响口服蛋白质和胜肽市场的一个决定性趋势是，人们越来越关注 "标靶递送" 机制。这标誌着人们的关注点从单纯关注蛋白质摄取量转向优先考虑吸收效率和生物利用度。这一转变反映出人们更深刻地认识到，这些产品的有效性主要取决于蛋白质和胜肽在体内递送和吸收的效率，而不是摄取的总量。因此，递送技术的创新已成为该领域产品开发的核心。

优化障碍

由于这些分子的固有特性，特别是其大分子量和高亲水性，口服蛋白质和胜肽市场的成长面临巨大的挑战。这些特性使得分子难以有效穿过肠道上皮细胞，对吸收进入体循环构成重大障碍。 由于肠壁具有选择性通透性，较大、吸水性较强的分子难以有效穿过此屏障，导致口服生物利用度有限。

目录

第一章：摘要整理：口服蛋白质与胜肽市场

第二章：报告概述

  • 研究框架
    • 研究目标
    • 市场定义
    • 市场区隔
  • 研究方法
    • 市场规模估算
    • 质性研究
    • 量化研究
    • 依地区划分的原始调查受访者细分
    • 资料三角验证
    • 研究假设

第三章：口服蛋白质与胜肽市场概述

  • 产业价值链分析
    • 原料供应商
    • 研发（研发）
    • 活性药物成分生产
    • 药物製剂与给药技术
    • 合约生产组织 (CMO)
    • 法规与品质管制
    • 行销与分销
    • 终端用户
  • 行业展望
    • 生物製药产业概览
    • 口服生物製药需求不断成长
    • 医院引领治疗应用，而运动健身产业推动需求成长
    • 给药技术进步
    • 聚焦生物製药研发与产品线拓展
    • 不断发展的监管支持与框架
  • PESTLE 分析
  • 波特五力分析
    • 供应商议价能力
    • 买方议价能力
    • 威胁替代品
    • 新进入者的威胁
    • 竞争强度
  • 市场成长与展望
    • 市场收入估计与预测（2020-2035）
    • 基于推进法的价格分析
  • 市场吸引力分析
    • 基于推进法
  • 实务见解（分析师建议）

第四章 竞争格局概览

  • 市场集中度
  • 公司占有率分析（基于价值，2025）
  • 竞争格局分析与标竿分析

第五章：口服蛋白质与胜肽市场分析

第六章：北美口服蛋白质与胜肽市场分析

第七章：欧洲口服蛋白与胜肽市场分析

第八章：亚太地区口服蛋白质和胜肽市场分析

第九章：中东和非洲口服蛋白和胜肽市场分析

第十章：南美洲口服蛋白与胜肽市场分析

第11章 企业简介

  • AbbVie Inc.
  • Biocon Limited
  • Chiesi Farmaceutici S.p.A.
  • Entera Bio Ltd.
  • Groupe Sanofi
  • Johnson &Johnson Services, Inc.
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Proxima Concepts
  • Synergy Pharma
  • Tarsa Therapeutics, Inc.
  • others

第12章 附录

简介目录
Product Code: AA01261660

The global oral proteins and peptides market is undergoing rapid expansion, with its valuation reaching USD 9.50 billion in 2025 and projected to soar to USD 47.33 billion by 2035. This impressive growth corresponds to a compound annual growth rate (CAGR) of approximately 17.42% during the forecast period from 2026 to 2035. Such a robust trajectory highlights the increasing importance and adoption of oral protein and peptide therapies across various healthcare sectors.

A pivotal development in 2025 was the strategic portfolio restructuring by industry giants Nestle Health Science and Danone. Both companies have taken significant steps to bridge the traditional divide between the food and pharmaceutical sectors, recognizing the potential of oral proteins and peptides as functional ingredients that deliver targeted health benefits. Their investments have heavily focused on enzymatic hydrolysis technologies, which break down long-chain proteins into smaller, bioactive peptides.

Noteworthy Market Developments

The oral protein and peptides market is distinctly marked by the strong involvement of well-established pharmaceutical companies that prioritize research and development focused on creating oral alternatives to traditional injectable therapies. These companies recognize the growing demand for less invasive treatment options and are actively investing in innovative technologies to improve the effectiveness and bioavailability of oral formulations.

A notable development in 2025 was the strategic portfolio restructuring by major players such as Nestle Health Science and Danone. Both companies have taken decisive steps to integrate and blur the lines between the food and pharmaceutical sectors, aiming to leverage their expertise in nutrition and health science to deliver products that offer targeted therapeutic benefits. Central to their approach has been substantial investment in enzymatic hydrolysis technologies, which break down long-chain proteins into smaller, bioactive peptides.

Addressing past supply challenges, pharmaceutical giants Eli Lilly and Novo Nordisk have made significant financial commitments to expand their manufacturing capabilities. Between 2024 and 2025, these companies collectively pledged over $18 billion to upgrade and enlarge peptide synthesis facilities located in key regions like North Carolina and Denmark. This expansion effort aims to stabilize supply chains, meet increasing global demand, and accelerate the development and production of advanced peptide-based therapies.

Core Growth Drivers

The increasing prevalence of chronic diseases such as diabetes, cancer, and gastrointestinal disorders is playing a significant role in driving the demand for oral protein and peptide therapies. These conditions often require long-term, sometimes lifelong, medication regimens, many of which traditionally involve painful and inconvenient daily injections. The burden of frequent injections not only affects patient compliance but also impacts quality of life, making the search for effective oral alternatives a critical priority in healthcare.

Emerging Opportunity Trends

A defining trend shaping the oral protein and peptides market is the growing emphasis on "Targeted Delivery" mechanisms, which mark a significant shift from simply focusing on the quantity of protein consumed to prioritizing the efficiency of absorption and bioavailability. This evolution reflects a deeper understanding that the effectiveness of these products largely depends on how well the proteins and peptides are delivered and absorbed in the body, rather than just the raw amount ingested. As a result, innovation in delivery technologies has become central to product development in this sector.

Barriers to Optimization

The market growth of oral proteins and peptides faces significant challenges due to the inherent characteristics of these molecules, particularly their large molecular size and high hydrophilicity. These properties make it difficult for the molecules to effectively cross the intestinal epithelium, a critical barrier for absorption into the systemic circulation. The intestinal lining is selectively permeable, and larger, water-attracting molecules often struggle to penetrate this barrier efficiently, resulting in limited bioavailability when administered orally.

Detailed Market Segmentation

By Product, nutritional proteins, particularly isolates, hydrolysates, and clinical formulations, dominate the oral protein and peptides market, capturing over 48% of the product share. This leadership stems from their evolution beyond niche bodybuilding supplements to becoming essential components in both clinical nutrition and active lifestyle diets. These protein forms offer superior bioavailability and a rich amino acid profile, making them highly effective for a wide range of health applications. Their versatility allows them to meet the needs of patients requiring medical nutrition support as well as individuals seeking preventative wellness through optimized dietary intake.

By Application, sports and performance nutrition currently dominates the oral protein and peptides market, holding a significant share of 38.56%. This leadership is largely due to a successful rebranding effort that has transformed these products from being perceived solely as fuel for elite athletes to being recognized as essential "active nutrition" for the broader public. The shift reflects a growing awareness among everyday consumers about the benefits of protein and peptide supplementation for general health, fitness, and recovery, rather than just competitive performance. This broader appeal has expanded the market beyond traditional athlete demographics, reaching individuals who pursue an active lifestyle in various forms.

By End User, the "Sports & Fitness Enthusiasts" segment holds the largest share of the oral protein and peptides market, commanding 41.67% of total market revenue. This dominance is closely tied to the unprecedented rise in global participation in physical activity, which has created a substantial and consistently engaged consumer base. As more people around the world commit to active lifestyles, the demand for protein and peptide supplements that support muscle recovery, endurance, and overall performance has surged, driving growth within this particular end-user category.

By Source, despite the increasing attention and discussion around plant-based protein alternatives, animal-derived proteins continue to dominate the oral protein and peptides market. Sources such as whey, casein, and collagen hold the largest market share, accounting for over 34% of the total, largely because of their superior amino acid profiles and higher bioavailability. These characteristics make animal-derived proteins more effective in promoting muscle repair, recovery, and overall health benefits compared to many plant-based options, which often lack one or more essential amino acids or have lower absorption rates.

Segment Breakdown

By Product Type

  • Nutritional Proteins
  • Bioactive Peptides
  • Therapeutic Peptides

By Source

  • Animal-Derived Proteins
  • Plant-Derived Proteins
  • Synthetic/Fermentation-Derived Peptides
  • Collagen-Derived Peptides

By Application

  • Sports & Performance Nutrition
  • Weight Management
  • Immune Health Support
  • Digestive & Gut Health
  • Bone & Joint Health
  • Metabolic Health
  • Therapeutic/Clinical Nutrition
  • Other Functional Applications

By End-User

  • Sports & Fitness Enthusiasts
  • Health & Wellness Consumers
  • Medical & Clinical Nutrition Patients
  • Aging Population / Elderly
  • Lifestyle / Weight Management Users

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Geography Breakdown

  • North America holds a commanding position in the global oral protein and peptides market, accounting for 38.23% of the total market share. This dominant status is the result of strategic and aggressive capital deployment combined with a regulatory environment that is highly supportive of chronic disease management. The region's leadership in this sector is not coincidental but rather the outcome of deliberate structural investments and policies aimed at fostering growth and innovation within the oral protein and peptides industry.
  • A significant factor underpinning North America's dominance is the substantial influx of investment directed toward domestic manufacturing capabilities and clinical validation processes. These investments are designed to ensure that the region remains at the forefront of developing and producing oral peptide products, which are increasingly important for treating a variety of chronic conditions. A notable example of this trend is CordenPharma's decision in July 2024 to invest USD 500 million into its facility in Colorado.

Leading Market Participants

  • AbbVie Inc.
  • Biocon Limited
  • Chiesi Farmaceutici S.p.A.
  • EnteraBio Ltd.
  • Groupe Sanofi
  • Johnson & Johnson Services, Inc.
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Proxima Concepts
  • Synergy Pharma
  • Tarsa Therapeutics, Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Oral Protein and Peptides Market

Chapter 2. Report Description

  • 2.1. Research Framework
    • 2.1.1. Research Objective
    • 2.1.2. Market Definitions
    • 2.1.3. Market Segmentation
  • 2.2. Research Methodology
    • 2.2.1. Market Size Estimation
    • 2.2.2. Qualitative Research
      • 2.2.2.1. Primary & Secondary Sources
    • 2.2.3. Quantitative Research
      • 2.2.3.1. Primary & Secondary Sources
    • 2.2.4. Breakdown of Primary Research Respondents, By Region
    • 2.2.5. Data Triangulation
    • 2.2.6. Assumption for Study

Chapter 3. Oral Protein and Peptides Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Material Suppliers
    • 3.1.2. Research & Development (R&D)
    • 3.1.3. API Manufacturing
    • 3.1.4. Formulation & Drug Delivery Technology
    • 3.1.5. Contract Manufacturing Organizations (CMOs)
    • 3.1.6. Regulatory & Quality Control
    • 3.1.7. Marketing & Distribution
    • 3.1.8. End Users
  • 3.2. Industry Outlook
    • 3.2.1. Biopharmaceutical Industry overview
    • 3.2.2. Rising Demand for Oral Delivery of Biologics
    • 3.2.3. Hospitals Lead Therapeutic Adoption, While Sports & Fitness Segment Drives Volume Demand Stats
    • 3.2.4. Advances in Drug Delivery Technologies
    • 3.2.5. Focus on Biopharmaceutical R&D and Pipeline Expansion
    • 3.2.6. Regulatory Support and Framework Evolutions
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Pricing Analysis, By Propulsion Type
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Propulsion Type
  • 3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Oral Protein And Peptides Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases & Increased healthcare spending
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Product Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Nutritional Proteins
        • 5.2.1.1.2. Bioactive Peptides
        • 5.2.1.1.3. Therapeutic Peptides
    • 5.2.2. By Source
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Animal-Derived Proteins
        • 5.2.2.1.2. Plant-Derived Proteins
        • 5.2.2.1.3. Synthetic/Fermentation-Derived Peptides
        • 5.2.2.1.4. Collagen-Derived Peptides
    • 5.2.3. By Application
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Sports & Performance Nutrition
        • 5.2.3.1.2. Weight Management
        • 5.2.3.1.3. Immune Health Support
        • 5.2.3.1.4. Digestive & Gut Health
        • 5.2.3.1.5. Bone & Joint Health
        • 5.2.3.1.6. Metabolic Health
        • 5.2.3.1.7. Therapeutic/Clinical Nutrition
        • 5.2.3.1.8. Other Functional Applications
    • 5.2.4. By End users
      • 5.2.4.1. Sports & Fitness Enthusiasts
      • 5.2.4.2. Health & Wellness Consumers
      • 5.2.4.3. Medical & Clinical Nutrition Patients
      • 5.2.4.4. Aging Population / Elderly
      • 5.2.4.5. Lifestyle / Weight Management Users
    • 5.2.5. By Region
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. North America
          • 5.2.5.1.1.1. The U.S.
          • 5.2.5.1.1.2. Canada
          • 5.2.5.1.1.3. Mexico
        • 5.2.5.1.2. Europe
          • 5.2.5.1.2.1. Western Europe
            • 5.2.5.1.2.1.1. The UK
            • 5.2.5.1.2.1.2. Germany
            • 5.2.5.1.2.1.3. France
            • 5.2.5.1.2.1.4. Italy
            • 5.2.5.1.2.1.5. Spain
            • 5.2.5.1.2.1.6. Rest of Western Europe
          • 5.2.5.1.2.2. Eastern Europe
            • 5.2.5.1.2.2.1. Poland
            • 5.2.5.1.2.2.2. Russia
            • 5.2.5.1.2.2.3. Rest of Eastern Europe
        • 5.2.5.1.3. Asia Pacific
          • 5.2.5.1.3.1. China
          • 5.2.5.1.3.2. India
          • 5.2.5.1.3.3. Japan
          • 5.2.5.1.3.4. South Korea
          • 5.2.5.1.3.5. Australia & New Zealand
          • 5.2.5.1.3.6. ASEAN
            • 5.2.5.1.3.6.1. Indonesia
            • 5.2.5.1.3.6.2. Malaysia
            • 5.2.5.1.3.6.3. Thailand
            • 5.2.5.1.3.6.4. Singapore
            • 5.2.5.1.3.6.5. Rest of ASEAN
          • 5.2.5.1.3.7. Rest of Asia Pacific
        • 5.2.5.1.4. Middle East & Africa
          • 5.2.5.1.4.1. UAE
          • 5.2.5.1.4.2. Saudi Arabia
          • 5.2.5.1.4.3. South Africa
          • 5.2.5.1.4.4. Rest of MEA
        • 5.2.5.1.5. South America
          • 5.2.5.1.5.1. Argentina
          • 5.2.5.1.5.2. Brazil
          • 5.2.5.1.5.3. Rest of South America

Chapter 6. North America Oral Protein And Peptides Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Product Type
    • 6.2.2. By Application Type
    • 6.2.3. By Source
    • 6.2.4. By End users
    • 6.2.5. By Country

Chapter 7. Europe Oral Protein And Peptides Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Product Type
    • 7.2.2. By Application Type
    • 7.2.3. By Source
    • 7.2.4. By End users
    • 7.2.5. By Country

Chapter 8. Asia Pacific Oral Protein And Peptides Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Product Type
    • 8.2.2. By Application Type
    • 8.2.3. By Source
    • 8.2.4. By End users
    • 8.2.5. By Country

Chapter 9. Middle East & Africa Oral Protein And Peptides Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Product Type
    • 9.2.2. By Application Type
    • 9.2.3. By Source
    • 9.2.4. By End users
    • 9.2.5. By Country

Chapter 10. South America Oral Protein And Peptides Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Product Type
    • 10.2.2. By Application Type
    • 10.2.3. By Source
    • 10.2.4. By End users
    • 10.2.5. By Country

Chapter 11. Company Profile (Company Overview, Company Timeline, Organization Structure, Key Product landscape, Financial Matrix, Key Customers/Sectors, Key Competitors, SWOT Analysis, Contact Address, and Business Strategy Outlook)

  • 11.1. AbbVie Inc.
  • 11.2. Biocon Limited
  • 11.3. Chiesi Farmaceutici S.p.A.
  • 11.4. Entera Bio Ltd.
  • 11.5. Groupe Sanofi
  • 11.6. Johnson & Johnson Services, Inc.
  • 11.7. Novo Nordisk A/S
  • 11.8. Oramed Pharmaceuticals Inc.
  • 11.9. Pfizer Inc.
  • 11.10. Proxima Concepts
  • 11.11. Synergy Pharma
  • 11.12. Tarsa Therapeutics, Inc.
  • 11.13. others

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators